Search research articles
Contact Us
Filters
Showing results (1-10 of 15) with videos related to
Page
of 2
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 29, 2020
Treatment Algorithm for Advanced ALK-Rearranged NSCLC
Edyta Maria Urbanska, Jens Benn Sørensen, Eric Santoni-Rugiu
Translational Lung Cancer Research
|
March 21, 2025
Alectinib impressively enters the adjuvant setting for early-stage <i>ALK</i>-rearranged non-small cell lung cancer and outperforms chemotherapy-let's define who benefits the most
Eric Santoni-Rugiu, Jens Benn Sørensen, Edyta Maria Urbanska
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 7, 2024
Finding One Treatment for All Advanced EGFR-positive NSCLC-An Infinite Task
Edyta Maria Urbanska, Jens Benn Sørensen, Eric Santoni-Rugiu
Chinese Clinical Oncology
|
September 11, 2024
Befotertinib in first-line treatment for Chinese non-small cell lung cancer patients harboring common EGFR-mutations reveals similar efficacy to other third-generation EGFR-TKIs but somewhat different safety profile
Jens Benn Sørensen, Eric Santoni-Rugiu, Edyta Maria Urbanska
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 26, 2023
Efficacy of Brigatinib After Progression on Alectinib or Ceritinib: Does One Drug Work in a Pretreated Heterogeneous ALK-Positive NSCLC Population?
Edyta Maria Urbanska, Jens Benn Sørensen, Eric Santoni-Rugiu
Journal of Thoracic Disease
|
June 17, 2026
Are lazertinib and osimertinib comparable for treating advanced <i>EGFR</i>-mutant non-small cell lung cancer?-insights and limitations from the MARIPOSA study
Edyta Maria Urbanska, Eric Santoni-Rugiu, Morten Grauslund, et al.
Clinical Lung Cancer
|
July 12, 2020
Intracranial Response of ALK<sup>+</sup> Non-Small-cell Lung Cancer to Second-line Dose-escalated Brigatinib After Alectinib Discontinuation Due to Drug-induced Hepatitis and Relapse After Whole Brain Radiotherapy Followed by Stereotactic Radiosurgery
Edyta Maria Urbanska, Eric Santoni-Rugiu, Linea Cecilie Melchior, et al.
International Journal of Molecular Sciences
|
July 12, 2025
Refining Criteria for Choosing the First-Line Treatment for Real-World Patients with Advanced <i>ALK</i>-Rearranged NSCLC
Edyta Maria Urbanska, Peter Rindom Koffeldt, Morten Grauslund, et al.
Clinics and Practice
|
June 2, 2021
Uncommon Presentation of Granulomatosis with Polyangiitis Mimicking Metastatic Lung Cancer
Edyta Maria Urbanska, Johanna Elversang, Bonnie Colville-Ebeling, et al.
International Journal of Molecular Sciences
|
January 10, 2026
Improvement of Diagnostics in NSCLC Patients with <i>MET</i> Exon 14 Mutations Using Complementary DNA/RNA-NGS and Identification of Two Novel Exonic Splicing Mutations
Edyta Maria Urbanska, Thomas Koed Doktor, Linea Cecilie Melchior, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 15) with videos related to
Sort By:
Page
of 2
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 29, 2020
Treatment Algorithm for Advanced ALK-Rearranged NSCLC
Edyta Maria Urbanska, Jens Benn Sørensen, Eric Santoni-Rugiu
Translational Lung Cancer Research
|
March 21, 2025
Alectinib impressively enters the adjuvant setting for early-stage <i>ALK</i>-rearranged non-small cell lung cancer and outperforms chemotherapy-let's define who benefits the most
Eric Santoni-Rugiu, Jens Benn Sørensen, Edyta Maria Urbanska
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 7, 2024
Finding One Treatment for All Advanced EGFR-positive NSCLC-An Infinite Task
Edyta Maria Urbanska, Jens Benn Sørensen, Eric Santoni-Rugiu
Chinese Clinical Oncology
|
September 11, 2024
Befotertinib in first-line treatment for Chinese non-small cell lung cancer patients harboring common EGFR-mutations reveals similar efficacy to other third-generation EGFR-TKIs but somewhat different safety profile
Jens Benn Sørensen, Eric Santoni-Rugiu, Edyta Maria Urbanska
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 26, 2023
Efficacy of Brigatinib After Progression on Alectinib or Ceritinib: Does One Drug Work in a Pretreated Heterogeneous ALK-Positive NSCLC Population?
Edyta Maria Urbanska, Jens Benn Sørensen, Eric Santoni-Rugiu
Journal of Thoracic Disease
|
June 17, 2026
Are lazertinib and osimertinib comparable for treating advanced <i>EGFR</i>-mutant non-small cell lung cancer?-insights and limitations from the MARIPOSA study
Edyta Maria Urbanska, Eric Santoni-Rugiu, Morten Grauslund, et al.
Clinical Lung Cancer
|
July 12, 2020
Intracranial Response of ALK<sup>+</sup> Non-Small-cell Lung Cancer to Second-line Dose-escalated Brigatinib After Alectinib Discontinuation Due to Drug-induced Hepatitis and Relapse After Whole Brain Radiotherapy Followed by Stereotactic Radiosurgery
Edyta Maria Urbanska, Eric Santoni-Rugiu, Linea Cecilie Melchior, et al.
International Journal of Molecular Sciences
|
July 12, 2025
Refining Criteria for Choosing the First-Line Treatment for Real-World Patients with Advanced <i>ALK</i>-Rearranged NSCLC
Edyta Maria Urbanska, Peter Rindom Koffeldt, Morten Grauslund, et al.
Clinics and Practice
|
June 2, 2021
Uncommon Presentation of Granulomatosis with Polyangiitis Mimicking Metastatic Lung Cancer
Edyta Maria Urbanska, Johanna Elversang, Bonnie Colville-Ebeling, et al.
International Journal of Molecular Sciences
|
January 10, 2026
Improvement of Diagnostics in NSCLC Patients with <i>MET</i> Exon 14 Mutations Using Complementary DNA/RNA-NGS and Identification of Two Novel Exonic Splicing Mutations
Edyta Maria Urbanska, Thomas Koed Doktor, Linea Cecilie Melchior, et al.
Page
of 2